Navigation Links
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones
Date:5/21/2009

NuSil Technology announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones.

Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil Technology (http://www.nusil.com), a leading formulator and manufacturer of silicone compounds for the healthcare and pharmaceutical industries, announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones effective 1-May-2009. As part of the acquisition, NuSil will begin transitioning the manufacturing of seven key Simethicone products used in pharmaceutical applications. Financial details of the transaction were not disclosed.

"The Bluestar Pharmaceutical Simethicone products are a great complement to the current NuSil Simethicone product line. NuSil's 30 years experience working with healthcare-related materials, including silicones for drug delivery systems and long-term implants, provides us with the working regulatory knowledge needed to support the product line for our customers," said Richard Compton, CEO and co-founder of NuSil. "This acquisition, when combined with our ingestible Simethicone product line that we acquired from GE Advanced Materials in 2004, strengthens our position in the pharmaceutical industry as a leading Simethicone supplier with a broad product offering and global distribution capabilities."

Simethicones are wide spectrum antifoam and defoaming products which have been used successfully in various industries including pharmaceutical, food and cosmetics. In the pharmaceutical industry, Simethicones have shown efficacy as antifoams in processes such as biological fermentations and in the manufacture of antibiotics. Simethicones are also widely used as active pharmaceutical ingredients in anti-flatulent formulations. NuSil's current Simethicone products meet various monographs including the European Pharmacopeia for Simethicone and the United States Pharmacopeia for Simethicone Emulsion (contact NuSil for specific references). As part of this acquisition, NuSil will transfer the manufacturing of the Bluestar Silicones Pharmaceutical Simethicone business to NuSil's FDA registered facility in Bakersfield, California.

NuSil formulates standard and customized silicone products based on the vast, unique array of properties the material provides. Product quality is assured by the company's Quality System, which begins with an effective design protocol and continues up the supply chain from vendor qualification through re-inspection of finished product inventories.

For more information on NuSil's silicones for pharmaceuticals, call 805-684-8780 or visit http://www.nusil.com/simethicone.

About NuSil Silicone Technology
NuSil is a leading formulator of silicone compounds for healthcare, aerospace, electronics and other applications requiring precise, predictable materials performance. ISO-9001 certified since 1994, NuSil operates state-of-the-art laboratories and processing facilities in North America and provides on-site, in-person application engineering support worldwide. More information about NuSil Technology can be found at http://www.nusil.com.

Media Contact
Stephanie Supina
NuSil Technology
805-684-8780 x221

# # #

Read the full story at http://www.prweb.com/releases/NuSil/Simethicone/prweb2447954.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
2. Recondo Technology Announces Two New Board Members
3. Nanotechnology May Simplify Antibiotic Treatment
4. SMS Technology Places Eye Health Educational Information at Hispanics Fingertips
5. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
6. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
7. Leading Healthcare Technology Companies Launch National Physician Education Program on Stimulus and Electronic Health Records
8. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
9. NewCardio to Introduce Technology at Heart Rhythm Society Conference
10. Zila & Experts Testify at Congressional Hearing on Innovative Technology for Veterans; Urge Broader Use of ViziLite(R) Plus by VA for Oral Cancer Screening
11. Smart Phone, ePRO, and eDiary Technology Advances for Clinical Trials, Market Research, and Registries Reported by assisTek
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 
(Date:5/26/2016)... CT; Scottsdale, AZ (PRWEB) , ... ... ... insights consultancy, Actûrus , is happy to announce the launch of ... thinking of the funnel model to reflect the dynamic landscape of modern ...
(Date:5/26/2016)... Viejo, California (PRWEB) , ... May 26, 2016 , ... ... Transition Plugin for FCPX. , "This new layered style transition tool will ... said Christina Austion - CEO of Pixel Film Studios. , TranSweep is an ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... In ... to the mainland by a single drawbridge, citizens formed an organization, Madeira Beach United, ... congested traffic and change the small town center to a high rise urban environment. ...
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, ... filled with chemical-laden beauty products, one company is going against the norm with a ... Hippie. The rising star in the green space is proud to announce its latest ...
(Date:5/26/2016)... ... May 26, 2016 , ... Women’s athletic apparel company ... second pop-up shop for three consecutive weekends. The pop-up shop is a great ... community, a community full of women who appreciate the most premium goods and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology: